ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

Centers May Become More specialized, Klausner Tells AACI

April 26, 1996

Anil Potti Reprimanded by North Carolina Licensure Board

December 9, 2011

Brown Disagrees With Staff, Subgroup On Dichlorvos, Says It Is a Carcinogen

September 2, 1977

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

January 10, 2003

PCI Files Application For Research Base COP

September 9, 1994

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012